



February 8, 2018

## Terumo Revises the Full-Year Results Forecast for FY 2017

TOKYO, JAPAN – February 8, 2018 – Terumo Corporation (TSE: 4543) today announced that it revised the full-year results forecast for the year ending March, 2018 (FY 2017).

### 1. Full-year results forecast for FY 2017 (From April 1, 2017 to March 31, 2018)

	Net sales (Million yen)	Operating income (Million yen)	Ordinary income (Million yen)	Profit attributable to owners of parent (Million yen)	Net income per share (Yen)
Prior forecast	575,000	82,000	79,500	53,000	150.58
Revised forecast	588,000	92,000	89,500	76,000	215.70
Change	13,000	10,000	10,000	23,000	
Change (%)	2.3%	12.2%	12.6%	43.4%	
(Reference) Results for the prior fiscal year	514,164	76,578	68,552	54,225	150.15

### 2. Reasons for the revision

Net sales, operating income and ordinary income are expected to exceed the prior forecast due to the following reasons. Each business has shown stable growth, and the yen has depreciated more than assumed in our initial forecasts.

In addition to the reason stated above, profit attributable to owners of parent is expected to exceed the prior forecast greatly, given the temporary reduction of income taxes, that came mainly from the revaluation of the deferred tax assets and liabilities, which happened as a result of the enactment of the Tax Cuts and Jobs Act (US tax reform).

Though Terumo had been suspending its manufacturing of the Angio-Seal™ Vascular Closure product line since September 20, 2017 due to Hurricane Maria, Terumo resumed production in November and then released its products in January, 2018.

### About Terumo Corporation

Tokyo-based Terumo Corporation is one of the world's leading medical device manufacturers with over \$5 billion in sales and operations in more than 160 nations. Founded in 1921, the company develops, manufactures and distributes world-class medical devices including products for use in cardiothoracic surgery, interventional procedures and transfusion medicine; the company also manufactures a broad array of syringe and hypodermic needle products for hospital and physician office use. Terumo contributes to society by providing valued products and services to the health care

market and by responding to the needs of health care providers and the people they serve. Terumo Corporation's shares are listed on the first section of the Tokyo Stock Exchange (No. 4543, Reuters symbol <4543.T>, or Bloomberg 4543: JP) and is a component of the Nikkei 225, Japan's leading stock index.

### **Disclaimer**

Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts on projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition. The market share information in this press release is partly derived from our own independent research.

###